Thermobalancing therapy emerges as drug-free option for BPH, chronic prostatitis, back pain and kidney stones
Oxford, UK, Feb. 21, 2026 (GLOBE NEWSWIRE) -- Therapeutic Dr Allen’s Devices…
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
February 20, 2026 15:10 ET | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British…
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:…
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:…
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
January 23, 2026 17:00 ET | Source: Corvus Pharmaceuticals, Inc. SOUTH SAN…
IQ Option Marks Its 12th Anniversary and Launches a $56,000 Tournament
ST. JOHN'S, Antigua and Barbuda, Dec. 3, 2025 /PRNewswire/ -- The online…
Hydreight Technologies Acquires 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase up to 40%, and Establishes Strategic Partnership
Not for distribution to United States newswire services or for dissemination in…
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares for Gross Proceeds of $345 Million
SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
